About ALTG

The Australasian Lung Cancer Trials Group (ALTG) is Australia and New Zealand's lung and thoracic cancer clinical research group. The ALTG is a multi-disciplinary organization dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers and improving the quality of life of these patients, carers and families in Australia and New Zealand through the coordination and facilitation of high quality clinical research.

The ALTG collaborates with a number of organizations including the NHMRC Clinical Trials Centre (CTC) and Peter MacCallum Cancer Centre. Both of these groups are leaders in Australia for the design, conduct, analysis and publication of oncology clinical trials, including working with both Australia and international collaborative groups.

Why become a member

  • Quarterly newsletter
  • Support
    for the development of investigator-initiated studies
  • Access to a professional network
    for lung and thoracic cancer research, including clinicians, nursing staff, industry affiliates and consumer representatives

Upcoming Events

7 October 2016 12.00am ESMO, Copenhagen Denmark
21 October 2016 12.00am ** NEW** ALTG Members’ Meeting/Workshop, Location TBD
28 October 2016 12.00am - 5.00pm 2nd ALTG Preceptorship in Lung Cancer, Sydney NSW The 2nd ALTG Preceptorship in Lung Cancer: APPLICATIONS OPEN Conveners:   A/Prof Nick Pavlakis & A/Prof Eva Segelov Location:      Park Royal Darling Harbour. Sydney, NSW Dates:            Friday 28th & Saturday 29th October 2016 Applications for the 2016 Preceptorship have CLOSED. Many thanks to all those who have applied and the committee looks forward to the two day event.  This two day intensive learning course is based on review of literature to understand the evolution of treatment for lung cancer. The committee has decided to direct this year's focus to "NSCLC: Medical therapy of early and advanced disease".  The areas that will be addressed include:
  1. Adjuvant therapy in resected NSCLC
  2. Locally advanced NSCLC- radical therapy
  3. Metastatic NSCLC chemotherapy with or without biological therapy
  4. Metastatic NSCLC immunotherapy
  5. Metastatic NSCLC Mutation targeted therapy
Learning will be in small group interactive sessions aimed at advanced trainees and junior consultants in Medical, Radiation and Surgical Oncology, and Respiratory Medicine. The format will be that of a short course (retreat) with small groups allocated to a preceptor, and active participation from attendees with regard to reviewing papers and presenting cases. The organising committee would like to thank the sponsors of the 2nd ALTG Preceptorship in Lung Cancer for their support and contributions: Bristol-Myers Squibb, Merck Sharp & Dohme, Boehringer Ingelheim, and Roche. [table id=13 /] How to Apply Applications for the 2016 Preceptorship have CLOSED. Applications for the 2017 Preceptorship will be announced in the new year.   If you have any questions, please email enquiries@altg.com.au.